Jared Weiss, MD

In this companion article, Dr. Jared Weiss provides key insights into recent advancements in the standard of care for extensive-stage small cell lung cancer and examines challenges affecting treatment.

Dr. Jared Weiss of the University of North Carolina Lineberger Comprehensive Cancer Center considers treatment challenges and unmet needs in the current standard-of-care management of extensive-stage small cell lung cancer.

Jared Weiss, MD, shares insight into current unmet needs in extensive-stage small cell lung cancer and provides advice to researchers about the importance of clinical trials studying differential treatments and biomarkers.

Expert oncologist Jared Weiss, MD, considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed small cell lung cancer.

Thought leader in lung cancer, Jared Weiss, MD, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.

Key opinion leader in thoracic oncology, Jared Weiss, MD, discusses the role of second-line treatment for relapsed ES-SCLC after first-line therapy and maintenance immunotherapy.

Jared Weiss, MD, reviews first-line treatment options for extensive-stage small cell lung cancer and highlights the current standard-of-care regimen: carboplatin, etoposide, and a PD-L1 inhibitor with the possible addition of trilaciclib.

An expert in the management of lung cancer, Jared Weiss, MD, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 64-year-old woman with extensive-stage small cell lung cancer.

Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.